Cyclacel Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
-€21.54K - Cost of goods sold
€4.31K - Gross profit
-€25.85K - SG&A expenses
€5.51M - R&D expenses
€2.28M - EBITDA
-€8.97M - D&A
€2.58K - EBIT
-€8.92M - Interest expenses
€0.00 - EBT
-€4.67M - Tax expenses
€849.49K - Net income
-€5.52M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€4.07M - Changes in working capital
-€3.74M - Operating cash flow
-€3.81M - Capex
€0.00 - Other investing cash flow
€0.00 - Net investing cash flow
€0.00 - Total cash dividends paid
-€35.32 - Issuance of common stock
€6.40M - Debt repayment
€0.00 - Other financing cash flow
-€264.56K - Net financing cash flow
€4.53M - Foreign exchange effects
-€44.01K - Net change in cash
-€2.47M - Cash at end of period
€3.68K - Free cash flow
-€3.81M
Balance sheet
- Cash and cash equivalents
€3.68K - Cash and short-term investments
€3.68K - Total receivables
€43.08K - Inventory
€0.00 - Other current assets
-€42.98K - Total current assets
€3.78K - Property, plant & equipment
€15.51 - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€15.51 - Total assets
€3.79K - Accounts payable
€190.40K - Short-term debt
€0.00 - Other current liabilities
-€189.75K - Total current liabilities
€654.78 - Long-term debt
€8.62K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€8.62 - Total liabilities
€663.39 - Common stock
€1.72K - Retained earnings
-€380.61K - Other equity
€0.00 - Total equity
€3.13K - Total liabilities and shareholders' equity
€3.79K
Company information
- Market capitalization
€9.05M - Employees
12 - Enterprise Value
€3.59M
Company ratios
- Gross margin
-
120.0% Much better than peer group: -789,206,364,470.0% - EBITDA margin
-
41,648.0% Much better than peer group: -1,866,868,554,349.7% - EBIT margin
-
41,432.0% Much better than peer group: -1,974,135,970,570.1% - EBT margin
-
21,688.0% Much better than peer group: -1,894,410,513,042.0% - Net margin
-
25,632.0% Much better than peer group: -1,894,410,938,704.9% - ROE
-
-176,480.3% Much worse than peer group: -117.9% - ROA
-
-145,603.3% Much worse than peer group: -187.0% - Asset turnover
-
-568.1% Much worse than peer group: 7.5% - FCF margin
-
17,709.2% Much better than peer group: -1,578,240,225,879.5% - FCF yield
-42.2% - Efficiency ratio
-41,548.0% - Net sales per employee
-
-€1.79K - Net income per employee
-
-€460.07K